Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients With Relapsed Immune Thrombocytopenia

NCT03395210 is registered in ClinicalTrials.gov with Principia Biopharma, a Sanofi Company as lead sponsor.

NCT NCT03395210
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03395210 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients With Relapsed Immune Thrombocytopenia
Lead sponsor
Principia Biopharma, a Sanofi Company
Phase
Phase 2
Overall status
Completed
Start date
March 22, 2018
Completion date
December 11, 2025
Enrollment
86 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

immune thrombocytopenia